Drug Trial Radar · NCT01219855
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
Last checked: Nov 19, 2026Latest source record: Aug 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Oct 2010
Primary completion
Nov 2011
Study completion Nov 2011
Sponsor
- Lead sponsor
- OPKO Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 13, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with chronic kidney disease (CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT).
Conditions
- Chronic Kidney Disease
- Secondary Hyperparathyroidism
- Vitamin D Insufficiency
Interventions
Cohort 1 CTAP101 Capsules- 60µgDrug
60µg of CTAP101 capsules given once daily for 42 days.
Cohort 1 CTAP101 Capsules - 90µgDrug
90µg of CTAP101 capsules given once daily for 42 days.
Cohort 1 Matching Sugar CapsuleDrug
Placebo capsules given once daily for 42 days.
Cohort 2 CTAP101 Capsules - 30µgDrug
30µg of CTAP101 capsules given once daily for 42 days.
Cohort 2 Matching Sugar CapsuleDrug
Placebo capsules given once daily for 42 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion (%) of Subjects With Serum 25-hydroxyvitamin D ≥30 ng/mL (PP).Time frame: 6 weeks
- Mean Percent Change From Baseline in Plasma Intact Parathyroid Hormone (iPTH) to End of Treatment (Per Protocol Population)Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
OPKO Health, Inc
Bannockburn, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.